WCG Institute Podcast: Pioneers of Clinical Research
Developing Novel Treatments for Rare Disorders: A Look at MPS I with Dr. Emil Kakkis
Jan 13, 2020 · 19 min
Play episode

In this episode, WCG’s President of Patient Advocacy, Steve Smith, talks with Emil Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx Pharmaceuticals and President of the non-profit EveryLife Foundation for Rare Diseases organization. Known for his work in developing an enzyme replacement therapy for the rare disorder MPS I and his connection to the Ryan Foundation, Dr. Kakkis shares with us his experiences in being involved in bringing drugs to market and forming relationships with patients along the way. 

Clear search
Close search
Google apps
Main menu